Filing Analysis
Fractyl Health, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 10, 2026. The company successfully elected three Class II directors and ratified the appointment of Ernst & Young LLP as its independent auditor for the 2026 fiscal year.
📋 Key Facts
- Annual Meeting held on June 10, 2026.
- Quorum achieved with 112,236,206 shares represented (approximately 70.7% of outstanding shares).
- Marc Elia, Clive Meanwell, and Ian Sheffield were elected as Class II directors for three-year terms.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Fractyl Health announced positive one-year results from its REVEAL-1 Cohort study, demonstrating that the Revita procedure helps patients maintain weight loss after discontinuing GLP-1 medications.
📋 Key Facts
- Patients maintained approximately 78% of their prior GLP-1-induced weight loss at one year post-Revita procedure.
- 33% of participants continued to lose weight one year after discontinuing GLP-1 therapy.
- 100% of patients in the cohort maintained at least 5% of their GLP-1-induced weight loss through one year.
- Mean total body weight change was 5.3% ± 2.1% (n=15) at one year.
- No procedure-related serious adverse events were reported; mild events occurred in 36% of participants within the first month.
Fractyl Health, Inc. (GUTS) furnished its financial results for the first quarter ended March 31, 2026, along with a corporate update. The filing is a routine quarterly disclosure and does not contain any immediate material changes to the company's structure or operations.
📋 Key Facts
- Financial results for the quarter ended March 31, 2026, were announced on May 12, 2026.
- The company provided a corporate update alongside its financial performance.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- Fractyl Health is an emerging growth company as defined by the SEC.
Fractyl Health announced it has received Clinical Trial Application (CTA) authorization in the Netherlands to initiate a Phase 1/2 first-in-human study of RJVA-001. This candidate is the first from the company's Rejuva Smart GLP-1 gene therapy platform to enter clinical testing.
📋 Key Facts
- Received CTA authorization in the Netherlands on May 11, 2026
- RJVA-001 is the first clinical candidate from the Rejuva Smart GLP-1 gene therapy platform
- The authorized study is a Phase 1/2 first-in-human clinical trial
- The announcement was made via a press release furnished under Item 7.01
Fractyl Health announced its Q4 and full-year 2025 financial results and provided a corporate update. The company also updated its corporate presentation to include new post hoc analyses from its REMAIN-1 clinical study.
📋 Key Facts
- Financial results for the quarter and full year ended December 31, 2025, were announced on March 24, 2026.
- Updated corporate presentation for use in meetings with investors and analysts.
- Provided new post hoc analyses for the REMAIN-1 Midpoint Cohort 6-month results.
- Analyses evaluated the relationship between treatment effect, procedural dose (length of duodenal ablation), and prior GLP-1-induced weight loss.
Fractyl Health, Inc. received a deficiency notice from Nasdaq on March 13, 2026, because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has 180 days, until September 9, 2026, to regain compliance or face potential delisting.
🚩 Red Flags
- Minimum bid price deficiency (stock trading below $1.00).
- Explicit mention of a potential reverse stock split to cure the deficiency.
- Risk of delisting if compliance is not met within the 180-day grace period.
📋 Key Facts
- Notice received from Nasdaq on March 13, 2026, regarding non-compliance with Rule 5450(a)(1).
- Common stock bid price was below $1.00 for 30 consecutive business days.
- The compliance deadline is September 9, 2026.
- To regain compliance, the stock must close at $1.00 or higher for at least 10 consecutive business days.
- The company may transfer to the Nasdaq Capital Market or effect a reverse stock split to resolve the deficiency.
Fractyl Health announced the completion of participant randomization for its REMAIN-1 Pivotal Cohort, a study evaluating the Revita procedure for weight maintenance after GLP-1 therapy discontinuation. The company also provided updated 2026 clinical and regulatory milestones and reiterated its current cash guidance.
📋 Key Facts
- Completion of participant randomization in the REMAIN-1 Pivotal Cohort as of February 26, 2026.
- The REMAIN-1 study is a randomized, double-blind, sham-controlled trial.
- The study specifically targets weight maintenance in patients who have discontinued GLP-1 therapy.
- The company provided updated guidance on 2026 Revita clinical and regulatory milestones.
- Management reiterated previous cash guidance, suggesting no immediate change to their financial runway expectations.